Navigation Links
Mediterranean Diet And Exercise, Key To Good Health

Exercising for at least for half an hour a day and indulging in a Mediterranean diet, which is based on a rich serving of vegetables and fish, may be the key// to longevity and good health, highlights a new study conducted by the World Health Organization.

According to the study, exercising just 30 minutes a day can add five years to your life. Walking, cycling and even climbing the stairs are included in the tally, reported THE online edition of Daily Mail. Similarly, people who eat a Mediterranean diet also have health benefits.

Older people, in particular, who eat this diet, can expect to live longer. A healthy man of 60 who sticks to a Mediterranean menu could expect to live a year longer than a man who has not changed his diet, the study said.

WHO added that smoking knocks an average six years from one's life and women are likely to be affected more than men. The habit causes lung disease, strokes, oral cancer and heart disease. Every time you puff a cigarette you lose another 11 minutes.

Scientists have also found that a group of health-food fanatics had hearts 15 years younger than those of other people their age.

Edited IANS
'"/>




Page: 1

Related medicine news :

1. Mediterranean diet aids Asian masses
2. The Mediterranean magic: helpful in heart disease
3. Mediterranean Diet Lowers Inflammation Levels In Elderly
4. Risk Of Dementia May Be Reduced By Mediterranean Diet
5. Mediterranean Diet Effective in Staving off Risk of Alzheimer’
6. Mediterranean Diet And Exercise Increases Life Expectancy
7. Alzheimer’s Risk Lowered with Mediterranean Die
8. Moderate Exercise, Key To Breast Cancer Prevention
9. New Study Weighs Benefits of Exercise, Diets
10. Startling Expose – Physicians Often Have No Regular Source Of Health Car
11. Want a Healthy brew? Have some Tea!
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Controversial kidney transplant technique could provide lifeline for very ill patients 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 2Health News:Concord Coalition Report Shows Eagerness for Reform, Readiness to Make Tough Choices on Fiscal Priorities 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 1VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA 2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4586 5Jubilant to Work With Endo Pharmaceuticals on Drug Development 12582 1Jubilant to Work With Endo Pharmaceuticals on Drug Development 12582 2Jubilant to Work With Endo Pharmaceuticals on Drug Development 12582 3XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 1XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 2XELR8 Holdings Inc Hires Vice President of Strategy and Network Development 48585 3
Other Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7